Arbutus Biopharma Corp - FORM 10-Q - EX-32.1 - EXHIBIT 32.1 - August 7, 2015

Attached files

file filename
EX-3.1 - EXHIBIT 3.1 - Arbutus Biopharma Corpexh_31.htm
EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corpexh_312.htm
EX-10.1 - EXHIBIT 10.1 - Arbutus Biopharma Corpexh_101.htm
EX-10.3 - EXHIBIT 10.3 - Arbutus Biopharma Corpexh_103.htm
EX-10.4 - EXHIBIT 10.4 - Arbutus Biopharma Corpexh_104.htm
EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corpexh_322.htm
EX-10.7 - EXHIBIT 10.7 - Arbutus Biopharma Corpexh_107.htm
EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corpexh_311.htm
EX-10.9 - EXHIBIT 10.9 - Arbutus Biopharma Corpexh_109.htm
EX-10.8 - EXHIBIT 10.8 - Arbutus Biopharma Corpexh_108.htm
EX-10.6 - EXHIBIT 10.6 - Arbutus Biopharma Corpexh_106.htm
EX-10.5 - EXHIBIT 10.5 - Arbutus Biopharma Corpexh_105.htm
EX-10.14 - EXHIBIT 10.14 - Arbutus Biopharma Corpexh_1014.htm
EX-10.11 - EXHIBIT 10.11 - Arbutus Biopharma Corpexh_1011.htm
EX-10.10 - EXHIBIT 10.10 - Arbutus Biopharma Corpexh_1010.htm
EX-10.12 - EXHIBIT 10.12 - Arbutus Biopharma Corpexh_1012.htm
EX-10.13 - EXHIBIT 10.13 - Arbutus Biopharma Corpexh_1013.htm
10-Q - FORM 10-Q - Arbutus Biopharma Corpgfpf10q_080515.htm
EX-10.2 - EXHIBIT 10.2 - Arbutus Biopharma Corpexh_102.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, (the “Company”), for the quarter ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Mark Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

 

Date: August 6, 2015

     
  /s/ Mark Murray
  Name: Mark Murray
  Title: President and Chief Executive Officer

 

 

Stock widget

Investing forum

Arbutus Biopharma Corp Reports